RR-11a is a synthetic enzyme inhibitor of Legumain, an asparaginyl endopeptidase.
RR-11a 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Human bone marrow mesenchymal stromal cells (hBMSC-TERT)
50 µM
14 days
To evaluate the inhibitory effect of RR-11a on legumain activity and its reversal of TGF-β1-induced inhibition of osteoblast maturation. Results showed that RR-11a significantly inhibited legumain activity and completely reversed the inhibitory effect of TGF-β1 on osteoblast maturation.
Front Endocrinol (Lausanne). 2024 Sep 19;15:1445049
Mouse renal tubular epithelial cells (mRTECs)
100 nM
24 hours
To evaluate the protective effect of RR-11a on hypoxia-induced cell death. Results showed that RR-11a pretreatment improved cell survival and reduced lipid peroxidation levels.
Cell Death Dis. 2021 Jan 11;12(1):65
RR-11a 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
NOD/SCID mice
OCI-Ly3 xenograft DLBCL model
Intraperitoneal injection
0.2 mg/kg
Once daily for 12 days
Inhibition of legumain activity significantly suppressed tumor growth, reduced angiogenesis, and increased collagen deposition.
Sci Rep. 2016 Jul 28;6:30347
C57BL/6J mice
Myocardial infarction model
Intraperitoneal injection
20 mg/kg
Once daily for 29 days
To evaluate the effect of RR-11a on cardiac function and structural remodeling post-myocardial infarction. Results showed that RR-11a significantly improved cardiac function, reduced cardiac rupture rate, and attenuated left ventricular dilation and wall thinning.
Cell Death Dis. 2020 Nov 26;11(11):1014
Mice
Bilateral ischemia-reperfusion injury (IRI) model
Intraperitoneal injection
20 mg/kg
Single dose, observed up to 7 days post-IRI
To evaluate the protective effect of RR-11a on IRI-induced acute kidney injury. Results showed that RR-11a treatment significantly reduced serum creatinine and BUN levels, improved tubular injury, and ameliorated ferroptosis markers.
搜索
